ABBEY ROBINSON: Open Payments
NPI 1053000182 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,357 in 119 payments from 19 companies in 2025. Trend: 2023 $0 · 2024 $550 · 2025 $2,357
Food & beverage: $2,357
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 8 | $346 |
| ABBVIE INC. | 28 | $293 |
| Novo Nordisk Inc | 15 | $245 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $231 |
| Axsome Therapeutics, Inc. | 8 | $199 |
| Otsuka America Pharmaceutical, Inc. | 4 | $174 |
| Lilly USA, LLC | 9 | $149 |
| Kowa Pharmaceuticals America, Inc. | 1 | $114 |
| Amgen Inc. | 6 | $99 |
| Phathom Pharmaceuticals, Inc. | 6 | $91 |
Products named: AIRSUPRA, CAPLYTA, REXULTI, Wegovy, VRAYLAR, Symbravo, ZORYVE, VOQUEZNA.
Industry payments across AL — which companies pay providers there.
